Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round
X-COR’s innovative technology transforms support for patients with respiratory failure and includes COVID-19 treatment applications.
FRAMINGHAM, MASSACHUSETTS – November 12, 2020 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device for use in clinical trials. Alira Health’s investment arm, Alira Health Ventures, added X-COR Therapeutics in 2019 as a portfolio company and led the recent seed financing with syndication from Good Growth Capital, PiSA Biopharm, Flybridge Partners’ Graduate Syndicate, and other notable angel investors.
“X-COR Therapeutics is continuing to develop its novel filtration system and compatible dialysate strategy for clinical testing and regulatory assessment. Working with the Alira Health Ventures Team generated additional momentum for X-COR to advance development during the COVID-19 pandemic and the addition of Gabriele Brambilla to our board further accelerates our progress,” said Jayon Wang, CEO of X-COR.
“We are pleased with the X-COR Team’s progress through this unprecedented year and are proud to work with such an elite investor group supporting this important technology,” said Gabriele Brambilla, Alira Health’s CEO. “Alira Health Ventures is dedicated to nurturing innovative technologies and propelling development from concept to clinical evaluation for future commercialization. X-COR’s technology will be transformational in the lives of patients suffering from respiratory failure, and this funding is a key milestone in accelerating the development of this vital technology.”
About X-COR Therapeutics:
X-COR Therapeutics is a Boston-based medical device company creating the first commercially available carbon dioxide removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR’s novel technology is a patent-pending medical device and accompanying control algorithm that enables physicians to directly remove excess carbon dioxide from lung failure patients.
To learn more about X-COR, visit http://xcortherapeutics.com/
About Alira Health Ventures:
As part of Alira Health, Alira Health Ventures is an accelerator for an innovative group of portfolio companies positioned to launch the next breakthrough technologies in medical devices and pharmaceuticals. From discovery to commercialization, Alira Health Ventures invests in products that advance healthcare and impact patients’ lives.
Read the press release on Businesswire here.
Subscribe to our newsletter for the latest news, events, and thought leadership
Our locations around the globe
USA, Boston
1 Grant Street, Suite 400, Framingham, Boston,
MA 01702, USA
+1 (774) 777 5255
USA, San Francisco
San Francisco, CA 94108, USA
+1 (774) 777 5255
France
12 Rue Charlot
75003 Paris, France
+33 (0)9 72 16 55 57
Germany
Kurfürstenstraße 22
80801 Munich, Germany
+49 (89) 416 14 22-0
Italy
Via Carlo Ottavio
Cornaggia 10, 20123 Milan, Italy
+39 (02) 36680198
Spain
Carrer de Balmes, 206 – Ático 2 08006 Barcelona, Spain
+34 (0)93 737 65 70
Switzerland, Geneva
Campus Biotech Innovation Park
Avenue de Sécheron 15
1202 Geneva, Switzerland
+33 (7) 69677361
+41 (79) 5937886
Switzerland, Basel
Badenstrasse 3
4056 Basel, Switzerland
+41 (0)61 205 9669